文献速递传染病防控与疫情报告卫生政策与健康促进

更新:全国性电子烟或雾化产品使用相关肺损伤暴发中住院患者的产品、物质使用和人口学特征——美国,2019年8月至2020年1月

Update: Product, Substance-Use, and Demographic Characteristics of Hospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, August 2019-January 2020.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2020-01-17

CDC等机构持续调查全国性电子烟或雾化产品使用相关肺损伤(EVALI)暴发。截至2020年1月7日,在有物质使用数据的1979例(76%)患者中,1620例(82%)报告使用任何含四氢大麻酚(THC)产品,其中665例(34%)为仅使用THC产品;1128例(57%)报告使用任何含尼古丁产品,其中264例(13%)为仅使用尼古丁产品。在有THC产品来源数据的809例(50%)患者中,131例(16%)仅从商业来源获取,627例(78%)仅从非正式来源获取,51例(6%)从两类来源获取。13-17岁青少年比年龄较大组更可能从非正式来源获取THC和尼古丁产品。CDC建议不要使用含THC的电子烟或雾化产品,尤其是从非正式来源获取的产品;并建议考虑避免使用所有电子烟或雾化产品。

要点

  • 在有物质使用数据的1979例EVALI患者中,1620例(82%)报告使用任何含THC产品,665例(34%)为仅使用THC产品。
  • 在有THC产品来源数据的809例患者中,627例(78%)仅从非正式来源获取,131例(16%)仅从商业来源获取。
  • 13-17岁青少年比年龄较大组更可能从非正式来源获取THC和尼古丁产品。

核心结论

  • EVALI患者中从非正式来源获取含THC产品的高比例强化了CDC的建议:不要使用含THC的电子烟或雾化产品,尤其是从非正式来源获取的产品。
  • 尽管通过非正式来源获取含尼古丁产品总体不常见,但在18岁以下人群中较常见。
  • 在调查继续期间,CDC建议确保不面临风险的最佳方式是考虑避免使用所有电子烟或雾化产品。

研究设计与样本

  • 本报告更新了州卫生部门向CDC报告的EVALI患者数据中的人口学特征及自报的含THC和含尼古丁电子烟或雾化产品来源。
  • 截至2020年1月7日,在有物质使用数据的1979例(76%)患者中分析了物质使用情况。
  • 在有THC产品来源数据的809例(50%)患者及有尼古丁产品来源数据的613例(54%)患者中分析了产品来源。

主要发现

  • 在有物质使用数据的1979例(76%)患者中,1620例(82%)报告使用任何含THC产品,其中665例(34%)报告仅使用含THC产品。
  • 1128例(57%)报告使用任何含尼古丁产品,其中264例(13%)报告仅使用含尼古丁产品。
  • 在有THC产品来源数据的809例(50%)患者中,131例(16%)仅从商业来源获取,627例(78%)仅从非正式来源获取,51例(6%)从两类来源获取。
  • 在有尼古丁产品来源数据的613例(54%)患者中,421例(69%)仅从商业来源获取,103例(17%)仅从非正式来源获取,89例(15%)从两类来源获取。
  • 13-17岁青少年比年龄较大组更可能从非正式来源获取THC和尼古丁产品。

关键数值与推荐

  • CDC建议不要使用含THC的电子烟或雾化产品,尤其是从非正式来源获取的产品。
  • CDC建议确保不面临风险的最佳方式是考虑避免使用所有电子烟或雾化产品。

临床怎么用

  • 临床医生应了解EVALI患者中从非正式来源获取含THC产品的高比例,并据此强化CDC不建议使用含THC电子烟或雾化产品的建议。
  • 对于18岁以下人群,需注意其通过非正式来源获取含尼古丁产品较常见。
  • 在调查继续期间,可依据CDC建议告知公众考虑避免使用所有电子烟或雾化产品。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CDC, the Food and Drug Administration (FDA), state and local health departments, and public health and clinical stakeholders continue to investigate a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) (1). EVALI patients in Illinois, Utah, and Wisconsin acquired tetrahydrocannabinol (THC)-containing products primarily from informal sources (2,3). This report updates demographic characteristics and self-reported sources of THC- and nicotine-containing e-cigarette, or vaping, products derived from EVALI patient data reported to CDC by state health departments. As of January 7, 2020, among 1,979 (76%) patients with available data on substance use, a total of 1,620 (82%) reported using any THC-containing products, including 665 (34%) who reported exclusive THC-containing product use. Use of any nicotine-containing products was reported by 1,128 (57%) patients, including 264 (13%) who reported exclusive nicotine-containing product use. Among 809 (50%) patients reporting data on the source of THC-containing products, 131 (16%) reported acquiring their products from only commercial sources (i.e., recreational dispensaries, medical dispensaries, or both; vape or smoke shops; stores; and pop-up shops), 627 (78%) from only informal sources (i.e., friends, family, in-person or online dealers, or other sources), and 51 (6%) from both types of sources. Among 613 (54%) EVALI patients reporting nicotine-containing product use with available data on product source, 421 (69%) reported acquiring their products from only commercial sources, 103 (17%) from only informal sources, and 89 (15%) from both types of sources. Adolescents aged 13-17 years were more likely to acquire both THC- and nicotine-containing products from informal sources than were persons in older age groups. The high prevalence of acquisition of THC-containing products from informal sources by EVALI patients reinforces CDC's recommendation to not use e-cigarette, or vaping, products that contain THC, especially those acquired from informal sources. Although acquisition of nicotine-containing products through informal sources was not common overall, it was common among persons aged <18 years. While the investigation continues, CDC recommends that the best way for persons to ensure that they are not at risk is to consider refraining from the use of all e-cigarette, or vaping, products.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Ellington S, Salvatore PP, Ko J, et al. Update: Product, Substance-Use, and Demographic Characteristics of Hospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, August 2019-January 2020. MMWR Morb Mortal Wkly Rep. 2020. PMID: 31945038. doi:10.15585/mmwr.mm6902e2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。